8-K

0001193125-23-067628.txt : 20230310 0001193125-23-067628.hdr.sgml : 20230310 20230310162132 ACCESSION NUMBER: 0001193125-23-067628 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20230310 ITEM INFORMATION: Regulation FD Disclosure FILED AS OF DATE: 20230310 DATE AS OF CHANGE: 20230310 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Atara Biotherapeutics, Inc. CENTRAL INDEX KEY: 0001604464 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 460920988 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36548 FILM NUMBER: 23723954 BUSINESS ADDRESS: STREET 1: 2380 CONEJO SPECTRUM ST STREET 2: SUITE 200 CITY: THOUSAND OAKS STATE: CA ZIP: 91320 BUSINESS PHONE: 805-623-4244 MAIL ADDRESS: STREET 1: 2380 CONEJO SPECTRUM ST STREET 2: SUITE 200 CITY: THOUSAND OAKS STATE: CA ZIP: 91320 8-K 1 d481537d8k.htm 8-K 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 10, 2023 (March 10, 2023)

ATARA BIOTHERAPEUTICS, INC.

(Exact Name of Registrant as Specified in Its Charter)

Delaware

001-36548

46-0920988

(State or Other Jurisdiction

of Incorporation or Organization)

(Commission

File No.)

(IRS Employer

Identification No.)

2380 Conejo Spectrum Street, Suite 200

Thousand Oaks, CA

91320

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s Telephone Number, Including Area Code: (805) 623-4211

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading
Symbol(s)

Name of Each Exchange

on Which Registered

Common Stock, par value $0.0001 per share

ATRA

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

ITEM 7.01

Regulation FD Disclosure.

Atara Biotherapeutics, Inc., a Delaware corporation (the “Company”), currently maintains an account at Silicon Valley Bank (“SVB”) holding cash deposits of approximately $2 million, which amount the Company considers to be immaterial to its liquidity.

The information in this Item 7.01 is being furnished, not filed, pursuant to Regulation FD. Accordingly, the information in Item 7.01 of this report will not be incorporated by reference into any registration statement filed by the Company under the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated therein by reference. The furnishing of the information in this report is not intended to, and does not, constitute a determination or admission by the Company that the information in this report is material or complete, or that investors should consider this information before making an investment decision with respect to any security of the Company.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Atara Biotherapeutics, Inc.

By:		/s/ Utpal Koppikar
		Utpal Koppikar
		Executive Vice President, Chief Financial Officer

Dated: March 10, 2023

EX-101.SCH 2 atra-20230310.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 3 atra-20230310_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 4 atra-20230310_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 5 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information	Mar. 10, 2023
Cover [Abstract]
Amendment Flag	false
Entity Central Index Key	0001604464
Document Type	8-K
Document Period End Date	Mar. 10, 2023
Entity Registrant Name	ATARA BIOTHERAPEUTICS, INC.
Entity Incorporation State Country Code	DE
Entity File Number	001-36548
Entity Tax Identification Number	46-0920988
Entity Address, Address Line One	2380 Conejo Spectrum Street
Entity Address, Address Line Two	Suite 200
Entity Address, City or Town	Thousand Oaks
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	91320
City Area Code	(805)
Local Phone Number	623-4211
Written Communications	false
Soliciting Material	false
Pre Commencement Tender Offer	false
Pre Commencement Issuer Tender Offer	false
Security 12b Title	Common Stock, par value $0.0001 per share
Trading Symbol	ATRA
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false

XML 6 d481537d8k_htm.xml IDEA: XBRL DOCUMENT 0001604464 2023-03-10 2023-03-10 false 0001604464 8-K 2023-03-10 ATARA BIOTHERAPEUTICS, INC. DE 001-36548 46-0920988 2380 Conejo Spectrum Street Suite 200 Thousand Oaks CA 91320 (805) 623-4211 false false false false Common Stock, par value $0.0001 per share ATRA NASDAQ false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.atarabio.com//20230310/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d481537d8k.htm atra-20230310.xsd atra-20230310_lab.xml atra-20230310_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d481537d8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 23 }, "contextCount": 1, "dts": { "inline": { "local": [ "d481537d8k.htm" ] }, "labelLink": { "local": [ "atra-20230310_lab.xml" ] }, "presentationLink": { "local": [ "atra-20230310_pre.xml" ] }, "schema": { "local": [ "atra-20230310.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "atra", "nsuri": "http://www.atarabio.com/20230310", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d481537d8k.htm", "contextRef": "duration_2023-03-10_to_2023-03-10", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.atarabio.com//20230310/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d481537d8k.htm", "contextRef": "duration_2023-03-10_to_2023-03-10", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.atarabio.com//20230310/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.atarabio.com//20230310/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.atarabio.com//20230310/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.atarabio.com//20230310/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.atarabio.com//20230310/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.atarabio.com//20230310/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.atarabio.com//20230310/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.atarabio.com//20230310/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.atarabio.com//20230310/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.atarabio.com//20230310/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.atarabio.com//20230310/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.atarabio.com//20230310/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.atarabio.com//20230310/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.atarabio.com//20230310/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.atarabio.com//20230310/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.atarabio.com//20230310/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.atarabio.com//20230310/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.atarabio.com//20230310/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.atarabio.com//20230310/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.atarabio.com//20230310/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.atarabio.com//20230310/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.atarabio.com//20230310/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.atarabio.com//20230310/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 13 0001193125-23-067628-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-23-067628-xbrl.zip M4$L#!!0 ( *^":E;P--,$/P, $T+ 1 871R82TR,#(S,#,Q,"YX M)UFL+Z8Y\V;>?-*''VXK"==HK-!J$J7)* )4A2Z%6DRBQL;< M%D)$'XY>OCC\(X[AY/3L F*X

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